Edition:
United States

Wilex AG (WL6G.F)

WL6G.F on Frankfurt Stock Exchange

2.88EUR
16 Oct 2017
Change (% chg)

€0.01 (+0.28%)
Prev Close
€2.87
Open
€2.88
Day's High
€2.88
Day's Low
€2.88
Volume
372
Avg. Vol
5,636
52-wk High
€3.35
52-wk Low
€1.42

Latest Key Developments (Source: Significant Developments)

Wilex H1 sales revenue and income down at EUR 1.1 mln
Thursday, 13 Jul 2017 01:08am EDT 

July 13 (Reuters) - WILEX AG ::H1 SALES REVENUE AND INCOME TOTALING EUR 1.1 MILLION, A DECREASE OF 42% COMPARED TO PREVIOUS YEAR (EUR 1.9 MILLION.‍NET LOSS FOR FIRST HALF OF YEAR ROSE TO EUR 4.1 MILLION FROM EUR 2.4 MILLION FOR SAME PERIOD IN 2016​.CONFIRMS ITS GUIDANCE FOR CURRENT FISCAL YEAR PROVIDED AT END OF MARCH 2017.  Full Article

Wilex says unit Heidelberg Pharma signs research agreement with Takeda
Monday, 19 Jun 2017 11:14am EDT 

June 19 (Reuters) - WILEX AG ::SUBSIDIARY HEIDELBERG PHARMA SIGNS EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT OF ANTIBODY TARGETED AMANITIN CONJUGATES.‍UNDER TERMS OF AGREEMENT, HEIDELBERG PHARMA WILL PRODUCE ANTIBODY TARGETED AMANITIN CONJUGATES (ATACS) USING ANTIBODIES FROM TAKEDA'S PROPRIETARY PORTFOLIO FOR UP TO THREE UNDISCLOSED TARGETS​.‍UNDER LICENSE AGREEMENT, HEIDELBERG PHARMA WOULD BE ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT, REGULATORY AND SALES-RELATED MILESTONE PAYMENTS OF UP TO USD 113 MILLION FOR EACH PRODUCT CANDIDATE, AS WELL AS ROYALTIES​.  Full Article

Wilex successfully completes rights issue
Thursday, 11 May 2017 04:26am EDT 

May 11 (Reuters) - WILEX AG ::WILEX AG SUCCESSFULLY COMPLETES RIGHTS ISSUE.GROSS PROCEEDS FROM RIGHTS ISSUE OF ALMOST EUR 5.0 MILLION.  Full Article

Wilex says plans rights issue using authorised capital
Monday, 24 Apr 2017 04:02am EDT 

April 24 (Reuters) - Wilex AG ::Plans rights issue using authorised capital.To increase company's share capital using authorized capital from 12,927,564.00 euros by up to 2,040,816.00 euros to up to 14,968,380.00 euros ($16.27 million).To increase share capital by issuing up to 2,040,816 new shares with a notional value of 1.00 euro each and full entitlement to dividends effective 1 December 2016 in return for cash contributions.  Full Article

Wilex Q1 net loss widens to 2.0 million euros
Wednesday, 12 Apr 2017 01:19am EDT 

Wilex AG : Outlook for 2017: increase in sales revenue forecast; investments in proprietary atac pipeline . Financial guidance remains unchanged compared to that provided on 30 March 2017 . In first three months of fiscal year 2017, Wilex Group generated sales revenue and income totaling 0.6 million euros (previous year: 1.0 million euros) . Net loss for first three months of fiscal year increased to 2.0 million euros, as planned (previous year: 1.1 million euros) .Based on current planning and assuming planned corporate actions are carried out, company's financing is secured until end of Q2 of 2018.  Full Article

Wilex posts FY net loss of 6.4 million euros
Thursday, 30 Mar 2017 01:00am EDT 

Wilex AG : Financials in line with guidance . Outlook for 2017: increase in sales revenue forecast; higher investments in proprietary atac pipeline . Generated sales revenue and other income totaling 2.7 million euros ($2.90 million) in fiscal year 2016 (previous year: 3.9 million euros) . FY net loss for year was 6.4 million euros (previous year: 6.6 million euros) . Wilex group's FY operating result was -6.4 million euros in 2016 fiscal year (previous year: -6.5 million euros) . Expects to generate between 4.0 million euros and 6.0 million euros in sales revenue and other income (2016: 2.7 million euros) for 2017 fiscal year .Earnings before interest and taxes (EBIT) for 2017 fiscal year are projected to be between -6.0 million euros and -10.0 million euros (2016: -6.4 million euros).  Full Article

Wilex subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration
Wednesday, 26 Oct 2016 01:00am EDT 

Wilex AG : Subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration to develop novel antibody drug conjugates (ADC) .Collaboration aims at developing novel antibody drug conjugates (ADCS) to treat leukemias.  Full Article

Wilex 9-month net loss widens to 4.1 mln euros
Thursday, 13 Oct 2016 01:19am EDT 

Wilex AG : In first 9-month generated sales revenue and income totaling 2.3 million euros ($2.58 million), down 21 pct compared to previous year (2.9 million euros) . At 4.1 million euros, Wilex group's net loss for first nine months of financial year increased year-on-year from 3.5 million euros as a result of lower sales revenue . There is no change to guidance for Wilex Group for current financial year issued at end of march 2016 .Based on current planning company's financing has been secured into Q2 of 2017.  Full Article

Wilex H1 net loss up 26 pct at EUR 2.4 mln
Thursday, 14 Jul 2016 01:10am EDT 

Wilex AG : H1 sales revenue and income totalling 1.9 million euros ($2.11 million), down 17 percent on previous year (2.3 million euros) . Net loss for first half of year rose by 26 percent to 2.4 million euros from 1.9 million euros .There is no change to guidance for Wilex Group for current financial year issued at end of march 2016.  Full Article

Wilex granted a patent in Europe for the chemical synthesis of dihydroxyisoleucine
Tuesday, 28 Jun 2016 01:30am EDT 

Wilex AG : European patent office grants patent for chemical synthetic building block dihydroxyisoleucine for production of Amanitin .Patent has a term until 2033.  Full Article

BRIEF- WILEX AG adjusts FY guidance

* SAID ON MONDAY ANNOUNCED THAT IT HAS ADJUSTED ITS GUIDANCE FOR CURRENT FISCAL YEAR, WHICH WAS PUBLISHED IN MARCH 2017